Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AD
Addex Therapeutics Ltd American Depositary Shares
ADXN
Mkt Cap
$4.9M
Volume
11.23K
Next Earnings
December 3rd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AD
ADXN
AD
Addex Therapeutics Ltd American Depositary Shares
ADXN
News
·
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
Mkt Cap
$4.8M
Volume
11.23K
Next Earnings
December 3rd
Chart
Earnings
News
About
Insider
Filings
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
Addex Therapeutics invested CHF 2 million in Stalicla, a clinical-stage company focusing on precision medicine for neurodevelopmental disorders. The investment supports Stalicla's autism drug candidates and clinical trials, with Addex CEO Tim Dyer joining Stalicla's Board of Directors.
GlobeNewswire Inc. · Jun 30, 2025
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
Stalicla, a Swiss clinical-stage biotech company, secured CHF 2 million in financing from Addex Therapeutics to advance its precision medicine neurodevelopmental disorder programs, including preparing for Series C financing and progressing clinical trials for autism and substance use disorder treatments.
GlobeNewswire Inc. · Jun 30, 2025
Addex Shareholders Approve All Resolutions at Annual General Meeting
Addex Therapeutics reported a strong cash position of CHF2.8 million at the end of Q1 2025. The company's GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models, and it regained rights to its phase 2 mGlu2 PAM asset.
GlobeNewswire Inc. · Jun 25, 2025
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
Addex Therapeutics, a clinical-stage biopharmaceutical company, announced that it will issue its Q1 2025 financial results and provide a business update on June 19, 2025. The company's GABAB PAM candidate has demonstrated robust anti-tussive activity in multiple chronic cough preclinical models.
GlobeNewswire Inc. · Jun 18, 2025
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
Addex Therapeutics announced that it will present preclinical data on its GABAB positive allosteric modulator cough program at the American Cough Conference. The company's lead drug candidate is ready to start IND enabling studies.
GlobeNewswire Inc. · Jun 5, 2025
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
Addex Therapeutics announced that its partner Janssen Pharmaceuticals has returned the development and commercialization rights to ADX71149, a drug candidate for neurological disorders. Addex is now evaluating future development options for the program.
GlobeNewswire Inc. · Apr 17, 2025
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
Addex Therapeutics reported a net loss of CHF 1.5 million in Q3 2024, compared to a net profit of CHF 12.9 million in Q2 2024, primarily due to the sale of part of the business to Neurosterix. However, the nine-month results remain positive, with a net profit of CHF 8.3 million.
GlobeNewswire Inc. · Nov 11, 2024
Addex’s Partner Discontinues ADX71149 development in Epilepsy - GlobeNewswire
Addex Therapeutics announced that its partner Janssen Pharmaceuticals has discontinued the development of ADX71149 in epilepsy after the Phase 2 study did not meet the primary endpoint. The companies will continue to analyze the full data set to determine the future of the asset.
GlobeNewswire Inc. · Jul 22, 2024
Addex Presents Positive Results from GABAB PAM Cough - GlobeNewswire
Addex Therapeutics presented positive results from its GABAB positive allosteric modulator (PAM) chronic cough program at the 13th London International Cough Symposium. The GABAB PAM candidate showed significant and dose-dependent reduction in cough frequency, increased cough latency, and no signs of tolerance in animal models, with a wider safety margin compared to the GABAB agonist baclofen.
GlobeNewswire Inc. · Jul 15, 2024
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) - GlobeNewswire
Addex Therapeutics, a biopharmaceutical company, announced that its Head of Translational Science, Mikhail Kalinichev, will present on the antitussive activity of a novel GABAB receptor positive allosteric modulator in preclinical models of chronic cough at the Thirteenth London International Cough Symposium.
GlobeNewswire Inc. · Jul 12, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AD
ADXN
Addex Therapeutics Ltd American Depositary Shares
Buy
Sell
Market
Limit
Soon
ADXN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ADXN yet.
Related Tickers
Earnings